View ValuationVeradermics 将来の成長Future 基準チェック /26Veradermics利益と収益がそれぞれ年間53.2%と59.3%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に-13% 97.2%なると予測されています。主要情報53.2%収益成長率97.19%EPS成長率Pharmaceuticals 収益成長11.9%収益成長率59.3%将来の株主資本利益率-13.01%アナリストカバレッジLow最終更新日15 May 2026今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesライブニュース • May 13Veradermics Advances Oral Hair Loss Program With Positive Results and $766.8 Million FundingVeradermics reported positive Phase 2/3 topline results for its oral hair-loss candidate VDPHL01 in Study 302, supporting its potential as the first FDA-approved oral treatment for pattern hair loss in almost 30 years. The company completed enrollment in pivotal Phase 3 Study 304 in male pattern hair loss and continues to enroll patients in Phase 3 Study 306 in female pattern hair loss. Veradermics raised about $766.8 million through its IPO and follow-on offerings, which the company expects to use to fund operations into 2030 and advance its clinical programs. The combination of positive late-stage data and multiple ongoing Phase 3 programs places Veradermics at a key development point where regulatory and clinical decisions may become major value drivers. For investors, the sizeable cash position reduces near-term financing risk, while outcomes for VDPHL01 and future regulatory interactions remain central uncertainties to watch.お知らせ • Apr 30+ 1 more updateVeradermics, Incorporated has completed a Follow-on Equity Offering in the amount of $384.379 million.Veradermics, Incorporated has completed a Follow-on Equity Offering in the amount of $384.379 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 3,843,790 Price\Range: $100お知らせ • Apr 28Veradermics, Incorporated has filed a Follow-on Equity Offering.Veradermics, Incorporated has filed a Follow-on Equity Offering. Security Name: Common Stock Security Type: Common Stock Securities Offered: 3,350,000Seeking Alpha • Apr 28Veradermics: Positive VDPHL01 Data Strengthens Late-Stage Pipeline ThesisSummary Veradermics delivered robust Phase 2/3 data for VDPHL01, showing 30–33 hairs/cm² regrowth vs. 7/cm² placebo and placebo-like safety. MANE’s late-stage, oral, extended-release minoxidil targets a large, underserved cash-pay hair loss market, with rapid onset and high patient satisfaction. The current $3.7B market cap reflects high expectations for VDPHL01’s regulatory approval and commercialization as a first-in-class oral therapy. A strong cash position post-offering supports Phase 3 completion; execution on VDPHL01 is central to valuation and future stock momentum. Read the full article on Seeking Alphaお知らせ • Feb 10Veradermics, Incorporated Completes Enrollment in Second Pivotal Phase 3 Clinical Trial of VDPHL01 for Male Pattern Hair LossVeradermics, Incorporated announced completion of enrollment in its second Phase 3 registration-directed clinical trial evaluating VDPHL01 for the treatment of male pattern hair loss. Following the previously announced completion of enrollment in Veradermics' first Phase 2/3 trial, this milestone marks the completion of enrollment across both Phase 3 clinical trials of VDPHL01 in males, encompassing more than 1,000 participants. Investors are cautioned not to place undue reliance on these forward-looking statements, including statements regarding the timing of completion of and data from the Phase 3 clinical trials for VDPHL01 for thetreatment of male and female pattern hair loss; the release profile of VDPHL01 and whether the release profile will achieve its intended effect; whether Veradermics will successfully file a new drug application for VDPHL01; and the projected size of the market for pattern hair loss treatments. Veradermics' anticipation that its success will depend on the approval and successful commercialization of VDPHL01, which is its lead product candidate, and if Veradermics is unable to obtain regulatory approval for, and successfully commercialize, VDPHL01, or any other current or future product candidates, or experience significant delays in doing so, its business will be materially harm; risks related to preclinical and clinical development and that results of earlier studies and trials may not be predictive of future preclinical studies or clinical trial results; the risk that Veradermics may encounter substantial delays in preclinical and clinical trials, or may not be able to conduct or complete preclinical or clinical trials on the expected timelines, if at all; the risk that the U.S. Food and Drug Administration does not conclude that VDPHL01 satisfies the requirements for the Section 505(b)(2) regulatory approval pathway, or if the requirements for VDPHL01 under Section 505(b)(2") are not as Veradermics expects, the approval pathway for those product candidates takes longer or costs more than anticipated; the risk that adverse events or undesirable side effects are caused by Veradermics' product candidates; competition from other companies; risks related to developing Veradermics' sales, marketing and distribution capability; the risk that even if Veradermics obtains regulatory approval for VDPHL01 or any other product candidates, such products may fail to achieve market acceptance; the risk that the commercial opportunity for VDPHL01 or Any other current or future product candidates may be smaller than Veradermics expects; the cash-pay healthcare market for VDPHL01 may limit Veradermics' ability to increase sales or achieve profitability; risks relating to effectively maintaining, promoting and enhancing Veradermics' reputation and VDPHL01 brand recognition in a cost-effective manner; risks related to Veradermics' need to grow its organization; the ability of Veradermics to successfully execute its intellectual property strategy for VDPHL01 and risks related to Veradermic' need to grow its organization. the ability of Veradermic to successfully execute its intellectual property strategies for VDPHL01 and risk related to Veradermics's ability to obtain and maintain sufficient intellectual property protection for VDPHL01 and other current and any future product candidates and other proprietary technologies; risks related to ongoing regulatory obligations for any approved products; risks related to Verader mics' reliance on third parties for the manufacture of drug or biological substances for preclinical studies and clinical trials and expectations that Veradermics will continue to do so for commercialization of any product candidates that are approved for marketing; risks related to VeraderMics' reliance and expected continued reliance on third parties to conduct preclinical studies and clinical trials; global macro conditions; global macro and regulatory obligations for any approved products.お知らせ • Feb 04Veradermics, Incorporated has completed an IPO in the amount of $256.319999 million.Veradermics, Incorporated has completed an IPO in the amount of $256.319999 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 15,077,647 Price\Range: $17 Transaction Features: Sponsor Backed Offering業績と収益の成長予測NYSE:MANE - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/2028226-123-105N/A212/31/202726-108-103N/A212/31/2026N/A-108-107N/A43/31/2026N/A-98N/AN/AN/A12/31/2025N/A-83-72-72N/A9/30/2025N/A-62-52-52N/A12/31/2024N/A-27-24-24N/Aアナリストによる今後の成長予測収入対貯蓄率: MANE今後 3 年間、利益が出ない状態が続くと予測されています。収益対市場: MANE今後 3 年間、利益が出ない状態が続くと予測されています。高成長収益: MANE今後 3 年間、利益が出ない状態が続くと予測されています。収益対市場: MANEの収益 ( 59.3% ) US市場 ( 11.7% ) よりも速いペースで成長すると予測されています。高い収益成長: MANEの収益 ( 59.3% ) 20%よりも速いペースで成長すると予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: MANE 3 年以内に赤字になると予測されています。成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/15 11:26終値2026/05/15 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Veradermics, Incorporated 4 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。4 アナリスト機関Prakhar AgrawalCantor Fitzgerald & Co.Geoffrey MeachamCitigroup IncRoger SongJefferies LLC1 その他のアナリストを表示
ライブニュース • May 13Veradermics Advances Oral Hair Loss Program With Positive Results and $766.8 Million FundingVeradermics reported positive Phase 2/3 topline results for its oral hair-loss candidate VDPHL01 in Study 302, supporting its potential as the first FDA-approved oral treatment for pattern hair loss in almost 30 years. The company completed enrollment in pivotal Phase 3 Study 304 in male pattern hair loss and continues to enroll patients in Phase 3 Study 306 in female pattern hair loss. Veradermics raised about $766.8 million through its IPO and follow-on offerings, which the company expects to use to fund operations into 2030 and advance its clinical programs. The combination of positive late-stage data and multiple ongoing Phase 3 programs places Veradermics at a key development point where regulatory and clinical decisions may become major value drivers. For investors, the sizeable cash position reduces near-term financing risk, while outcomes for VDPHL01 and future regulatory interactions remain central uncertainties to watch.
お知らせ • Apr 30+ 1 more updateVeradermics, Incorporated has completed a Follow-on Equity Offering in the amount of $384.379 million.Veradermics, Incorporated has completed a Follow-on Equity Offering in the amount of $384.379 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 3,843,790 Price\Range: $100
お知らせ • Apr 28Veradermics, Incorporated has filed a Follow-on Equity Offering.Veradermics, Incorporated has filed a Follow-on Equity Offering. Security Name: Common Stock Security Type: Common Stock Securities Offered: 3,350,000
Seeking Alpha • Apr 28Veradermics: Positive VDPHL01 Data Strengthens Late-Stage Pipeline ThesisSummary Veradermics delivered robust Phase 2/3 data for VDPHL01, showing 30–33 hairs/cm² regrowth vs. 7/cm² placebo and placebo-like safety. MANE’s late-stage, oral, extended-release minoxidil targets a large, underserved cash-pay hair loss market, with rapid onset and high patient satisfaction. The current $3.7B market cap reflects high expectations for VDPHL01’s regulatory approval and commercialization as a first-in-class oral therapy. A strong cash position post-offering supports Phase 3 completion; execution on VDPHL01 is central to valuation and future stock momentum. Read the full article on Seeking Alpha
お知らせ • Feb 10Veradermics, Incorporated Completes Enrollment in Second Pivotal Phase 3 Clinical Trial of VDPHL01 for Male Pattern Hair LossVeradermics, Incorporated announced completion of enrollment in its second Phase 3 registration-directed clinical trial evaluating VDPHL01 for the treatment of male pattern hair loss. Following the previously announced completion of enrollment in Veradermics' first Phase 2/3 trial, this milestone marks the completion of enrollment across both Phase 3 clinical trials of VDPHL01 in males, encompassing more than 1,000 participants. Investors are cautioned not to place undue reliance on these forward-looking statements, including statements regarding the timing of completion of and data from the Phase 3 clinical trials for VDPHL01 for thetreatment of male and female pattern hair loss; the release profile of VDPHL01 and whether the release profile will achieve its intended effect; whether Veradermics will successfully file a new drug application for VDPHL01; and the projected size of the market for pattern hair loss treatments. Veradermics' anticipation that its success will depend on the approval and successful commercialization of VDPHL01, which is its lead product candidate, and if Veradermics is unable to obtain regulatory approval for, and successfully commercialize, VDPHL01, or any other current or future product candidates, or experience significant delays in doing so, its business will be materially harm; risks related to preclinical and clinical development and that results of earlier studies and trials may not be predictive of future preclinical studies or clinical trial results; the risk that Veradermics may encounter substantial delays in preclinical and clinical trials, or may not be able to conduct or complete preclinical or clinical trials on the expected timelines, if at all; the risk that the U.S. Food and Drug Administration does not conclude that VDPHL01 satisfies the requirements for the Section 505(b)(2) regulatory approval pathway, or if the requirements for VDPHL01 under Section 505(b)(2") are not as Veradermics expects, the approval pathway for those product candidates takes longer or costs more than anticipated; the risk that adverse events or undesirable side effects are caused by Veradermics' product candidates; competition from other companies; risks related to developing Veradermics' sales, marketing and distribution capability; the risk that even if Veradermics obtains regulatory approval for VDPHL01 or any other product candidates, such products may fail to achieve market acceptance; the risk that the commercial opportunity for VDPHL01 or Any other current or future product candidates may be smaller than Veradermics expects; the cash-pay healthcare market for VDPHL01 may limit Veradermics' ability to increase sales or achieve profitability; risks relating to effectively maintaining, promoting and enhancing Veradermics' reputation and VDPHL01 brand recognition in a cost-effective manner; risks related to Veradermics' need to grow its organization; the ability of Veradermics to successfully execute its intellectual property strategy for VDPHL01 and risks related to Veradermic' need to grow its organization. the ability of Veradermic to successfully execute its intellectual property strategies for VDPHL01 and risk related to Veradermics's ability to obtain and maintain sufficient intellectual property protection for VDPHL01 and other current and any future product candidates and other proprietary technologies; risks related to ongoing regulatory obligations for any approved products; risks related to Verader mics' reliance on third parties for the manufacture of drug or biological substances for preclinical studies and clinical trials and expectations that Veradermics will continue to do so for commercialization of any product candidates that are approved for marketing; risks related to VeraderMics' reliance and expected continued reliance on third parties to conduct preclinical studies and clinical trials; global macro conditions; global macro and regulatory obligations for any approved products.
お知らせ • Feb 04Veradermics, Incorporated has completed an IPO in the amount of $256.319999 million.Veradermics, Incorporated has completed an IPO in the amount of $256.319999 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 15,077,647 Price\Range: $17 Transaction Features: Sponsor Backed Offering